相关实验视频
Updated: Jul 10, 2025

04:50
An Acupoint Catgut-embedding Therapy for Treating Obesity
Published on: April 4, 2025
427
肥胖支柱圆桌会议:通过高效的抗肥胖药物 (heAOMs) 减轻过重的体重
Harold Edward Bays1, Karli Burridge2, Jesse Richards3
1Diplomate of American Board of Obesity Medicine, President Louisville Metabolic and Atherosclerosis Research Center, University of Louisville Medical School, 3288 Illinois Avenue, Louisville, KY, 40213, USA.
Obesity pillars
|November 22, 2023
概括
新的抗肥胖药物 (AOMs) 可以导致显著的减肥,有时导致"太多的减肥". 本综述为经历过度减肥的患者使用高效的AOMs进行管理提供了指导.
科学领域:
- 肥胖医学 肥胖医学
- 药物治疗 药物治疗
- 代谢健康 代谢健康
背景情况:
- 从历史上看,抗肥胖药物 (AOM) 面临安全性和有效性有限的挑战.
- 最近的进展导致了具有更大的减肥能力的高效AOM (heAOM).
- 一个新出现的挑战是管理患者经历"太多的减肥"与这些heAOMs.
研究的目的:
- 为管理由于heAOMs而导致过度减肥的肥胖患者提供前景和临床指导.
- 用现代抗肥胖药物治疗来应对"太多减肥"的新挑战.
主要方法:
- 一个圆桌审查,涉及3名肥胖专家,在AOMs有临床经验.
- 讨论的重点是管理患者经历"太多的体重减轻"与heAOMs.
主要成果:
- 肥胖患者的治疗前教育至关重要,包括营养,水合,体力活动,行为修改和心理社会方面.
- 临床医生应该认识到客观和主观因素在定义"过度减肥",利用身体组成分析.
- 专家小组成员强调向患者告知与显著减肥相关的潜在医疗和心理社会变化.
结论:
- 建议采用结构化,算法化的方法来管理过度减肥的患者.
- 如果过度减肥归因于heAOM超级反应,患者教育和共享决策是关键.
- 管理选择包括剂量调整,暂时停止或停止heAOM,基于个体患者的需要.
相关概念视频
Antidepressant Drugs: MAOIs and Other Agents
248
Atypical antidepressants, including bupropion (Wellbutrin), mirtazapine (Remeron), nefazodone (Serzone), trazodone (Desyrel), and vilazodone (Viibryd), offer unique mechanisms of action. Bupropion weakly inhibits dopamine and norepinephrine reuptake, aiding depression treatment and smoking cessation, with a low risk of sexual dysfunction. Mirtazapine enhances serotonin and norepinephrine neurotransmission, leading to sedation, increased appetite, and weight gain. As a result, it helps treat...
248
Obesity
507
The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
507
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
672
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
672
Oral Hypoglycemic Agents: Biguanides and Glitazones
210
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
210
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
182
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
182
Glucagon-like Receptor Agonists
331
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
331

